Just 8.5M at .0011 next - as predicted.
Ignore VNDM at
Just 8.5M at .0011 next - as predicted.
Ignore VNDM at .0012 - he has never been a problem on INCC & moves up after getting hit for a M or so.
Tersis Technologies, Inc. (TERS) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...
Continue Reading
With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...
Continue Reading
Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...
Continue Reading
Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...
Continue Reading
Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...
Continue Reading
Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...
Continue Reading
Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...
Continue Reading
A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....
Continue Reading
Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...
Continue Reading
A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...
Continue Reading
Top 5 Most Recently Viewed Articles
Abaxx Technologies Submits Early Warning Report on MineHub Abaxx Technologies Inc. (CBOE: ABXX) (OTCQX: ABXXF) (“Abaxx” or the “Company”), a firm specializing in financial software and market infrastructure, has submitted an early warning report concerning its recent acquisition of shares in MineHub Technologies Inc. (“MineHub”). Abaxx, which has an indirect...
Continue Reading
NextGen Food Robotics Corporate Update NextGen Food Robotics Corp. (the “Company”) (CBOE: NGRB; OTC Pink: NGRBF; Frankfurt: O83) has released a significant bi-weekly update concerning its Management Cease Trade Order (MCTO). This update aligns with the guidelines set forth in National Policy 12-203 - Management Cease Trade Orders. MCTO Status Report Previously, the...
Continue Reading
The African Youth Survey 2024 dropped some serious knowledge about how young folks across Africa are sizing up global powers. With geopolitical shifts shaking things up, it ain't all sunshine and rainbows for traditional Western influences anymore—China and Russia are suddenly the stars of the show. Shifting Power Dynamics: Who's on Top? This survey, shared during key...
Continue Reading
Significant Movements in Axon Enterprise Options Investors are currently showing strong interest in Axon Enterprise (NASDAQ: AXON) options, displaying a bears outlook. This development is one that retail traders should pay attention to. Recent trading history suggests that significant players in the market have taken note of unusual activity concerning Axon options....
Continue Reading
Positive Phase II Results for InnoCare's ICP-488 in Psoriasis InnoCare Pharma, a prominent biopharmaceutical company specializing in innovative treatments for cancer and autoimmune diseases, has recently unveiled compelling results from its phase II clinical study of ICP-488. This TYK2 (Tyrosine Kinase 2) inhibitor has shown efficacy in patients battling...
Continue Reading